Therapeutic Agents for Steroid-refractory Immune Checkpoint Inhibitor-related Myocarditis: a Narrative Review

Overview

Journal Cardiovasc Diagn Ther

Publisher AME Publishing Company

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 12

PMID 39263485

Authors

Yang Wang

Shouchao Li

He Shi

Xue Guan

Qiang Wei

Dazhong Chen

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Immune checkpoint inhibitors (ICIs) have become one of the cornerstones of current oncology treatment, and immune checkpoint inhibitor-related myocarditis (IRM) is the most fatal of all immune checkpoint inhibitor-related adverse events (irAEs). Methylprednisolone pulse therapy (500-1,000 mg/day) is the initial treatment for IRM recommended by almost all relevant guidelines. However, subsequent treatment regimens remain unclear for patients who do not respond to methylprednisolone pulse therapy (who are defined as steroid-refractory patients). We propose a potential treatment approach for steroid-refractory IRM.

Methods: The PubMed and the Cochrane Library databases were searched using keywords related to IRM. Relevant English-language articles published from January 2000 to February 2024 were included in this narrative review.

Key Content And Findings: Abatacept is the preferred choice for the treatment of isolated steroid-refractory IRM. For rapidly progressive or interleukin-6 abnormally elevated steroid-refractory IRM, alemtuzumab or tocilizumab/tofacitinib are the preferred therapeutic agents, respectively. For steroid-refractory IRM comorbid with myositis or comorbid with myasthenia gravis, abatacept + ruxolitinib/mycophenolate mofetil (MMF)/intravenous immunoglobulin (IVIG), or MMF + pyridostigmine/IVIG are the preferred therapeutic agents, respectively.

Conclusions: The pathogenesis of steroid-refractory IRM and the treatment regimen remain unclear. A large number of studies need to be conducted to validate or update our proposed treatment approach.

References

Jespersen M, Fano S, Stenor C, Moller A . A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. Eur Heart J Case Rep. 2021; 5(11):ytab342. PMC: 8637790. DOI: 10.1093/ehjcr/ytab342. View

Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel L, Podgorny P . Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 2012; 14(10):1258-75. PMC: 3681879. DOI: 10.3109/14653249.2012.715243. View

Giancaterino S, Abushamat F, Duran J, Lupercio F, DeMaria A, Hsu J . Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis. HeartRhythm Case Rep. 2020; 6(10):761-764. PMC: 7573344. DOI: 10.1016/j.hrcr.2020.07.015. View

Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J . Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. Front Immunol. 2022; 13:1006860. PMC: 9515416. DOI: 10.3389/fimmu.2022.1006860. View

Riveiro-Barciela M, Soler M, Barreira-Diaz A, Bermejo S, Bruera S, Suarez-Almazor M . Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management. J Clin Med. 2022; 11(20). PMC: 9604376. DOI: 10.3390/jcm11205977. View

Su L, Liu C, Wu W, Cui Y, Wu M, Chen H . Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review. Front Cardiovasc Med. 2022; 9:898756. PMC: 9133913. DOI: 10.3389/fcvm.2022.898756. View

Jeyakumar N, Etchegaray M, Henry J, Lelenwa L, Zhao B, Segura A . The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma. Case Reports Immunol. 2020; 2020:5126717. PMC: 7355354. DOI: 10.1155/2020/5126717. View

Hu Y, Liu C, Jin S, Yi Z, Wang C, Pan X . A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer. BMC Pulm Med. 2023; 23(1):119. PMC: 10103507. DOI: 10.1186/s12890-023-02417-4. View

Dougan M, Luoma A, Dougan S, Wucherpfennig K . Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021; 184(6):1575-1588. PMC: 7979511. DOI: 10.1016/j.cell.2021.02.011. View

10.

Zhong P, Zhang C, Guan H, Yan J, He M, Zhou X . Myocarditis and myasthenia gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case report. Clin Case Rep. 2023; 11(3):e7039. PMC: 10032037. DOI: 10.1002/ccr3.7039. View

11.

Arangalage D, Delyon J, Lermuzeaux M, Ekpe K, Ederhy S, Pages C . Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. Ann Intern Med. 2017; 167(9):683-684. DOI: 10.7326/L17-0396. View

12.

Ke G, Chen P, Luo J, Huang J, Shang Y, Huang Y . Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor-induced myocarditis: A case series and review. Clin Cardiol. 2023; 46(12):1481-1487. PMC: 10716322. DOI: 10.1002/clc.24149. View

13.

Luo Y, Tang W, Zeng Q, Duan W, Li S, Yang X . Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment. Front Cardiovasc Med. 2021; 8:714460. PMC: 8415306. DOI: 10.3389/fcvm.2021.714460. View

14.

Barry T, Gallen R, Freeman C, Agasthi P, Pedrotty D, Yang M . Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. Am J Med Sci. 2021; 362(4):424-432. DOI: 10.1016/j.amjms.2021.04.018. View

15.

Kee W, Ng K, Lee J, Tan D . Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma. Clin Lung Cancer. 2022; 23(4):e293-e295. DOI: 10.1016/j.cllc.2021.12.001. View

16.

Guo C, Alexander M, Dib Y, Lau P, Weppler A, Au-Yeung G . A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer. 2019; 124:15-24. DOI: 10.1016/j.ejca.2019.09.009. View

17.

Onderko L, Heinrich R, Gosling K, Downs T, Afari M . Myocarditis Following Immune Checkpoint Inhibition With Pembrolizumab: Management in a Context of Steroid Intolerance. CJC Open. 2022; 4(10):854-857. PMC: 9568688. DOI: 10.1016/j.cjco.2022.07.002. View

18.

Faak F, Buni M, Falohun A, Lu H, Song J, Johnson D . Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer. 2023; 11(6). PMC: 10277540. DOI: 10.1136/jitc-2023-006814. View

19.

Levin A, Wildenberg M, van den Brink G . Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2016; 10(8):989-97. DOI: 10.1093/ecco-jcc/jjw053. View

20.

Fazel M, Jedlowski P . Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Case Reports Immunol. 2019; 2019:2539493. PMC: 6515062. DOI: 10.1155/2019/2539493. View